Posted On January 7, 2025 /
By Debbie Muse / Posted in Blog
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more
Posted On July 30, 2024 /
By Debbie Muse / Posted in Blog
Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
Posted On August 12, 2021 /
By Debbie Muse / Posted in Blog
Texas Retina Associates Collaborates on Gene Therapy Research for Rare, Inherited Retina Condition
Texas Retina Associates and the Retina Foundation of the Southwest (RFSW) have been working in collaboration on new gene therapy treatments for inherited blinding diseases for which there are no cures. Most
read more